

CLINICAL TRIAL INNOVATION

Learn how you can reduce the cost and complexity of your next clinical trial with PINC AI™ Applied Sciences

IMPACTS OF COMMON CLINICAL TRIAL CHALLENGES

Clinical trials often have extensive time and cost implications, and securing representation across all demographics and medical conditions pose yet another challenge.



TIME

80%

OF U.S. CLINICAL TRIALS FAIL TO MEET TARGETED RECRUITMENT TIMELINES¹ ~90 MONTHS

FOR NEW DRUGS/BIOLOGICS TO COMPLETE CLINICAL PHASE TRIALS²



COST

~\$2.6B

TO BRING A NEW DRUG TO MARKET³, FACTORING IN 14% SUCCESS RATE

COST OF TRIAL DELAYS FOR SPONSORS⁴

\$600K-\$8M

POOR SITE SELECTION INCREASES TRIAL COSTS BY



SEVERELY UNDER-REPRESENTED

5% VS. 15% 7% VS. 8%

20%



DIVERSITY

BLACK AMERICANS

LATINX SLIGHTLY UNDER-

REPRESENTED

>5%

NEED FOR AI

OF U.S. ADULTS WITH CANCER TAKE PART IN CLINICAL TRIALS²




COMPLEXITY

INCREASINGLY **COMPLEX TRIALS** MIXED WITH SPECIFIC INCLUSION/EXCLUSION CRITERIA CREATES **ENROLLMENT &** ELIGIBILITY CHALLENGES

RESEARCHERS OFTEN RELY ON THIRD PARTY DATA TO GAIN **ACCESS TO** NEW, DIVERSE PATIENT POOLS CAPABILITIES TO **IDENTIFY PATIENTS** & ENHANCE RESEARCH CAPABILITIES REQUIRING INCREASED COOPERATION BETWEEN IT AND RESEARCH **DEPARTMENTS**

The integration of Real-world Evidence can improve the efficacy, the generalizability and the relevance of clinical research.

HOW REAL-WORLD EVIDENCE IMPACTS CLINICAL TRIALS



TRIAL DESIGN IMPROVE INSIGHTS

IMPROVED

ON STUDY PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES



RECRUITMENT IDENTIFY SITES WITH

HIGH VOLUMES OF PATIENTS TO ENGAGE FOR TRIAL ENROLLMENT, ESSENTIALLY "FLIPPING THE FUNNEL" TO FIND THE PATIENTS FIRST



TRIALS UTILIZE SYNTHETIC

CONTROL ARMS TO MONITOR THEIR SAFETY AND EFFICACY OF THE INTERVENTIONS

How can Al and machine learning help improve the clinical trial process?

A GLIMPSE INTO THE FUTURE

CLINITHINK, NATURAL LANGUAGE PROCESSING (NLP) PROVIDES: MORE EFFICIENT TRIAL RECRUITMENT

IN PARTNERSHIP WITH

MORE PRECISE PATIENT


POTENTIAL TRIAL QUALIFICATIONS

IDENTIFICATION

AI ALERTS FOR

REGULATORY

REAL RESULTS



TRIAL SITE WORKLOAD REDUCED BY MORE THAN 90%

WITH AUTOMATED CNLP


UNSTRUCTURED SEARCH

AGILE END-TO-END SOLUTIONS

of clinical trials – from planning to submissions support and publications.

Partnering with PINC AI™ Applied Sciences can help ease the burden and complexity

6677 PROTOCOL MODELING AND FEASIBILITY



study to fail due to the way the protocol is

written if you get input from the health system. Myla Maloney, Chief Growth Officer, PINC AI™ Applied Sciences

There is no reason for a

HARNESS THE POWER OF PINC AI™ APPLIED SCIENCES CLINICAL TRIAL SOLUTIONS THROUGH: We can end up with a

lot more publications, and a lot more good research questions

just by having access to the data. MarieElena Cordisco, Associate Vice President, Clinical Trials, Research and Innovation, Nuvance Health

lot more information, a

CONTINUOUS INNOVATION Leverage Al and NLP to identify patients and overcome enrollment barriers. • Empower providers with point-of-care clinical decision support for early patient enrollment.

• Enhanced recruitment from data visibility and "flip the funnel" approach.

• Generate streamlined patient lists for study sites. UNRIVALED PATIENT INSIGHTS

UNMATCHED HEALTH SYSTEM ENGAGEMENT

Refined study designs and early protocol feedback.

Expertly assess qualitative study feasibility.

- Access unique data for creating external control arms. Ability to match clinical trial patients to PINC AI™ data for comprehensive patient tracking.
- **ACCELERATING INNOVATION:**

AVOID LOST REVENUES AND INCREASE SPEED TO COMMERCIALISM

COMPRESS STUDY TIMELINES

ACCURATE PROTOCOLS EARLY

INTRODUCE NEW CARE OPTIONS

SITE SELECTION, PROTOCOL OPTIMIZATION AND PROTOCOL DEVELOPMENT

OVERCOMING CHALLENGES AND MAXIMIZING PARTICIPATION

Partner with PINC AI™ Applied Sciences to optimize your next clinical trial, tackling improved patient outcomes, faster.



INCREASE DIVERSE PATIENT CATCHMENT AND ENROLLMENT ENGAGE WITH A WIDER CARE NETWORK IN THE COMMUNITY SETTING, IDENTIFY PATIENTS IN COMPLETE THERAPEUTIC AREAS

IMPROVE FEASIBILITY TO ELIMINATE COSTLY AMENDMENTS AND ENGAGE WITH TECHNICAL EXPERT PANELS TO ENSURE THE MOST



CASE STUDY: PROVEN RECRUITMENT SUCCESSES

IMPROVE BOTH PHYSICIAN AND PATIENT ENGAGEMENT

AFTER TAKING DATA VISIBILITY LEVERAGED DATA AND

RESULTED IN

ENROLLING 3X



OVER AS CRO.

PREMIER SITES WERE THE STUDY'S TOP ENROLLERS.

EXPECTED PATIENT VOLUMES, CUTTING ACTIVE STUDY TIME

IN HALF AND SAVING SIGNIFICANT MONEY.



RELATIONSHIPS TO ENROLL 50%

MORE SITES THAN

ALLOWING SHORTER STUDY LENGTH AND COST SAVINGS.

6677

Dr. Yosef Khan,

DCTs are a novel spin on trial design and trial conduct. I think by reducing the need for in-person visits and streamlining the clinical trial process, this can certainly improve efficiency and accuracy of trials.

Principal, Clinical Trials and Real World Evidence, PINC AI™ Applied Sciences

Contact us to learn more about how

LEARN MORE

PINC AI™ Applied Sciences can help streamline your next clinical trial.

1 "PATIENT RECRUITMENT AND RETENTIONSERVICES MARKET (2ND EDITION) 2021-2030: INDUSTRY ANALYSIS: MARKET SIZE: 2030" ROOTS ANALYSIS, MARCH 02,2021; 2 PASSUT, CHARLIE. "TREND OF LONGER TRIAL TIMELINES IS LIKELY TO CONTINUE," CENTERWATCH RSS, CENTERWATCH, 5 OCT. 2020;

3 HTTPS://MEDCITYNEWS.COM/2020/10/USE-VIRTUAL-VISITS-TO-ENHANCE-THE-PATIENT-CENTRICITY-OF-CLINICAL-TRIALS/;

5 MISETA E. BRING DOWN THE COST OF CLINICAL TRIALS WITH IMPROVED SITE SELECTION. CLINICAL LEADER. DECEMBER 19, 2013

4 CUTTING EDGE INFORMATION (PRESS RELEASE). 2005. CLINICAL TRIAL DELAYS COST PHARMACEUTICAL COMPANIES;